

# EpiVax | Platine

## Immunogenicity and Tolerance Seminar 2016



Venue: Hilton Apollolaan

---

**Session Moderator:  
To Be Announced**

### **Speakers:**

**Elly Van Riet, PhD**  
Senior Scientist  
Intravacc

**Prof. Annie De Groot, MD**  
Professor and Director, Institute of  
Immunology and Informatics,  
University of Rhode Island, CEO/CSO,  
EpiVax, Inc.

**Wim Jiskoot, PhD**  
Professor of Drug Development  
Leiden University Medical Center

**Marieke Van Ham, PhD**  
Immunopathology Department Head  
Sanquin

**Kees Melief, PhD**  
Chief Scientific Officer  
ISA Pharma

**Laurent Mascarell, PhD**  
Mucosal Immunology Head  
Stallergenes

**Tom Ottenhoff, MD, PhD**  
Professor of Immunology  
Leiden University Medical Center

**Stéphanie Delluc, PhD**  
Research and Development Director  
Platine Pharma Services

**Jérome Kerzerho, PhD**  
Research and Development Director  
Vaxeal

# Conference Agenda

## EpiVax|Platine Immunogenicity and Tolerance Seminar October 24th 2016

| Time         | Presenter  | Topic  |
|--------------|--|--|
| 9:40         |  | Arrival and Coffee<br><i>Insert Room Assignment</i>  |
| 10:00        |  | Introductions and Welcome  |
| 10:30        | <b>Elly Van Riet, PhD</b><br>Senior Scientist<br>Intravacc                                   | <b>Keynote Talk (20min + 10min Q&amp;A)</b><br><i>Immunogenicity of a Pertussis Outer Membrane Vesicle Vaccine</i>                                     |
| 11:00        | <b>Wim Jiskoot, PhD</b><br>Professor of Drug Development<br>Leiden University Medical Center | (20min + 10min Q&A)<br><i>Mouse Models for Assessing Protein Immunogenicity: Lessons and Challenges?</i>   |
| 11:30        | <b>Marieke Van Ham, PhD</b><br>Immunopathology<br>Sanquin                                    | (20min + 10min Q&A)<br><i>Title TBD</i>  |
| 12:00        | <b>Kees Melief, PhD</b><br>Chief Scientific Officer<br>ISA Pharma                            | (20min + 10min Q&A)<br><i>Title TBD</i>  |
| <b>12:30</b> | <b>Lunch (60 minutes)</b>  |  |
| 1:30         | <b>Laurent Mascarell, PhD</b><br>Mucosal Immunology Head<br>Stallergenes                     | (20min + 10min Q&A)<br><i>Biomarkers for Allergy Vaccines</i>  |
| 2:00         | <b>Tom Ottenhoff MD, PhD</b><br>Professor of Immunology<br>Leiden University Medical Center  | (20min + 10min Q&A)<br><i>Regulatory T cells in Tuberculosis: Friend or Foe?</i>   |
| 2:30         | <b>Stéphanie Delluc, PhD</b><br>R&D Director<br>Platine Pharma Services                      | (20min + 10min Q&A)<br><i>Cell-based Assays to Predict Biologic and Vaccine immunogenicity: Select The Method That Best Fits With Your Need</i>        |
| <b>3:00</b>  | <b>Break (15 minutes)</b>  |  |
| 3:15         | <b>Jérome Kerzerho,</b><br>R&D Director<br>Vaxeal  | (20min + 10min Q&A)<br><i>Title TBD</i>  |
| 3:45         | <b>Annie De Groot, MD</b><br>CEO/CSO<br>EpiVax   | (20min + 10min Q&A)<br><i>Newest developments on ISPRI immunogenicity prediction tools, de-immunization approaches and Tregitope immuno-modulators</i> |
| 4:15         | <b>All Speakers</b>  | Panel Discussion and Questions (45 minutes)<br>Topic: Relevance of Today's Talks   |
| 5:00         | <b>Speakers and Attendees</b>  | Award presentation (15 minutes)  |
| <b>5:15</b>  | <b>Networking session</b>  |  |



## **EpiVax:**

The team at **EpiVax**, Inc., led by Dr. Annie De Groot and Bill Martin, has pioneered the development of a set of immunoinformatics tools which allows researchers to predict the immunogenicity of peptides and proteins. The potential applications of this technology are vast: for instance, one could be to predict which vaccines will be most effective or which protein therapeutic drugs will have the possibility of eliciting an adverse immune response. It is a powerful research and development tool for designing effective and safe protein/peptide based therapeutics. The leaders of EpiVax, Inc. have been resolute in availing these tools to the research community. To that end, Dr. De Groot and her team, with funding from an NIH U19 grant, have developed the iVAX website where investigators can access their own set of genome sequences, proteins of interest, and tools for the analysis of vaccines and diagnostics. Using the iVAX toolkit, researchers can quickly and efficiently identify the most reactive proteins contained within a given pathogen, and optimize the antigenic content of vaccines. Furthermore, by selecting the highest quality epitopes from a protein sequence new antigens that are relevant for vaccine development can be discovered.



## **Platine:**

Founded in 1998, Indicia Biotechnology was acquired by Platine Pharma Services in June 2013. Based in the state-of-the-art Infectious Disease Centre of Lyon Gerland, Platine Pharma Services is the partner of choice of several drug development, cosmetics, CRO and IVD companies. From immunogenicity prediction in the early stages of lead selection to large clinical trial immunomonitoring, from assay development to method validation & optimization for CE IVD marking, from few to several thousands of biological samples, Platine Pharma Services offers its scientific expertise, its high quality standards and its large technological platform to support efficiently its customers in their product developments.

**For more information visit our event page: [http://bit.ly/EpiVax\\_Platine\\_Seminar\\_2016](http://bit.ly/EpiVax_Platine_Seminar_2016)**